| Tevimbra (tislelizumab-jsgr) / BeiGene |
AdvanTIG-211, NCT05809895: Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer |
|
|
| Withdrawn | 2 | 250 | NA | Ociperlimab, WCD118, Tislelizumab, VDT482, Paclitaxel, Nab-paclitaxel, Carboplatin, Placebo, Pembrolizumab, MK-3475, Gemcitabine | Novartis Pharmaceuticals | Triple Negative Breast Cancer | 07/29 | 07/29 | | |
IMM01-04, NCT05833984: Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas |
|
|
| Recruiting | 1b/2 | 309 | RoW | IMM01, SIRPα Fc, Tislelizumab | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Solid Tumor, Classic Hodgkin Lymphoma | 02/24 | 11/24 | | |
ACTRN12622001189718: An multi site clinical trial for patients with EBV associated Lymphomas - ALLG NHL36 |
|
|
| Not yet recruiting | 1/2 | 25 | | | Australasian Leukaemia and Lymphoma Group , Australasian Leukaemia and Lymphoma Group | Lymphoma | | | | |
ACTRN12622000547741: BICICL: BTK and Immune Checkpoint Inhibitor in Central Nervous System (CNS) Lymphoma |
|
|
| Not yet recruiting | 1/2 | 30 | | | Monash University, Monash University | Central Nervous System Lymphoma | | | | |
2018-000265-37: Phase 1-2 Study Investigating Safety, Tolerability, how the drug will be accepted in the body with treatment of BGB-A333 Alone and in Combination with Tislelizumab in Patients with Malignant Tumors Estudio en fase I-II para investigar la seguridad, la tolerabilidad, cómo se aceptará el fármaco en el cuerpo con el tratamiento de BGB-A333 solo y en combinación con tislelizumab en pacientes con tumores malignos |
|
|
| Not yet recruiting | 1/2 | 168 | Europe | Tislelizumab, BGB-A333, BGB-A317, Concentrate for solution for infusion | BeiGene, Ltd., BeiGene Ltd., | Anti-PD-L1 Monoclonal Antibody BGB-A333 Alone and in Combination with Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients with Advanced Solid Tumors El anticuerpo monoclonal anti-PD-L1 BGB-A333 en monoterapia y en combinación con el anticuerpo monoclonal anti-PD-1 tislelizumab en pacientes con tumores sólidos avanzados, BGB-A333 Alone and in Combination with Tislelizumab (BGB-A317) in Patients with Advanced Solid Tumors BGB-A333 solo y en combinación con tislelizumab en pacientes con tumores sólidos avanzados, Diseases [C] - Cancer [C04] | | | | |
2020-004163-12: Surufatinib in Combination With Tislelizumab in Advanced Solid Tumors Surufatinib en combinación con tislelizumab en tumores sólidos avanzados |
|
|
| Not yet recruiting | 1/2 | 107 | Europe | Surufatinib, Tislelizumab, HMPL-012, BGB-A317, Capsule, Concentrate for solution for infusion | Hutchison MediPharma Limited, Hutchison MediPharma Limited | Advanced Solid Tumors Tumores sólidos avanzados, Tumours Tumores, Diseases [C] - Cancer [C04] | | | | |
| Recruiting | 1/2 | 6 | RoW | tislelizumab and BCG | RenJi Hospital, BeiGene, Huidu Shanghai Medical Sciences Ltd | Urinary Bladder Neoplasms, Urologic Neoplasms, Urogenital Neoplasms, Antineoplastic Agents, Urinary Bladder Diseases, Tislelizumab Antineoplastic Agents, Immunological | 12/21 | 08/23 | | |
HEAIS001, NCT06022692: Hyperthermia Combined With Immune Checkpoint Inhibitor Therapy for Advanced Gastrointestinal Tumours |
|
|
| Completed | 1/2 | 18 | RoW | Water-filtered infrared A radiation whole-body hyperthermia (HECKEL 3000MT-4T, Germany), tislelizumab (BeiGene, China) combined with PD-1 inhibitor, Immune checkpoint inhibitor, PD-1 antibody | Pengyuan Liu, Zhejiang Hospital | Gastrointestinal Tumor | 05/22 | 08/23 | | |
NCT04979663: GEMOX Combined With Donafenib and Tislelizumab in Biliary Tract Cancer |
|
|
| Recruiting | 1/2 | 10 | RoW | Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab | Fudan University | Biliary Tract Carcinoma | 06/22 | 06/22 | | |
CRIS, NCT06303583: Neoadjuvant Chemoradiotherapy Followed by Sequential Immunotherapy for Thoracic Esophageal Squamous Cell Carcinoma |
|
|
| Enrolling by invitation | 1/2 | 30 | RoW | paclitaxel, carboplatin, tislelizumab, radiotherapy | Qiu Guoqin | Esophageal Squamous Cell Carcinoma | 08/24 | 12/26 | | |
2021-004155-16: Phase Ib study investigating dose, safety and efficacy of [177Lu]Lu-DOTA-TATE in patients with Extensive Stage Small Cell Lung Cancer (specific form of lung tumour) |
|
|
| Not yet recruiting | 1/2 | 200 | Europe | Tislelizumab, Solution for infusion, Kit for radiopharmaceutical preparation, Concentrate for solution for infusion, Lutathera, NETSPOT, Baize’an | Novartis Pharma AG, Novartis Pharma AG | Extensive-Stage Small Cell Lung Cancer, Specific form of lung tumour, Diseases [C] - Cancer [C04] | | | | |
TAXE-GC, NCT04963088: TISLELIZUMAB Combined With Anlotinib and Chemotherapy(XELOX) in the Treatment of Advanced Gastric Carcinoma |
|
|
| Recruiting | 1/2 | 66 | RoW | BGB-A317, Anlotinib, Oxaliplatin, Capecitabine | The First Affiliated Hospital with Nanjing Medical University | Gastric Cancer | 09/22 | 03/24 | | |
ChiCTR2100042125: ACC006 combined with Tislelizumab Injection in the treatment of non-small cell lung cancer phase Ib clinical study |
|
|
| Recruiting | 1/2 | 18 | China | ACC006 Oral Solution and Tislelizumab Injection | Sun Yat-Sen University Cancer Center ; Jiangsu Aidea Pharmaceutical Co.,Ltd, Self-financing | non-small cell lung cancer | | | | |
BGB-900-104, NCT03941873: A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) or Gastric/Gastroesophageal Junction Cancer (GC/GEJC) |
|
|
| Completed | 1/2 | 111 | RoW | Sitravatinib, Sitravatinib plus Tislelizumab, Sitravatinib and tislelizumab | BeiGene | Carcinoma, Hepatocellular, Gastric/Gastroesophageal Junction Cancer | 03/23 | 03/23 | | |
|
NCT04796857: Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL |
|
|
| Recruiting | 1/2 | 30 | RoW | PD-1 Antibody, Tislelizumab, Lenalidomide, revlimid | Huiqiang Huang | Non-GCB/ABC Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Grade IIIb, Transformed Lymphoma, EBV-Positive DLBCL, Nos, ALK-Positive Anaplastic Large Cell Lymphoma | 03/23 | 03/23 | | |
NCT06136910: Oncorine (H101) Combined With Tislelizumab and Chemotherapy in Previously Untreated Advanced Non-small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 30 | RoW | Recombinant human adenovirus type 5 injection (H101) combined with tirilizumab and platinum-containing two-drug chemotherapy | Fujian Cancer Hospital | Untreated Advanced Non-small Cell Lung Cancer | 05/24 | 12/25 | | |
ChiCTR2200060153: Study of the efficacy and safety of RC48 combined immunotherapy in neoadjuvant therapy for patients with HER2-positive muscle invasive bladder cancer |
|
|
| Not yet recruiting | 1/2 | 51 | China | tislelizumab+RC48 | West China Hospital, Sichuan University ; West China Hospital, Sichuan University, self-funded | Muscle-invasive urothelial carcinoma of the bladder (MIBC) | | | | |
ANTICIPATE, NCT04813107: A Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer |
|
|
| Recruiting | 1/2 | 79 | US, RoW | APL-1202 in combination with tislelizumab, Tislelizumab alone | Jiangsu Yahong Meditech Co., Ltd aka Asieris | Muscle Invasive Bladder Cancer | 11/23 | 03/24 | | |
NCT05842317: Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC |
|
|
| Recruiting | 1/2 | 60 | RoW | Lenvatinib Plus Tislelizumab, Transarterial Chemoembolization(TACE) | Peking Union Medical College Hospital | Hepatocellular Carcinoma | 04/24 | 11/24 | | |
NCT04577963: A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors |
|
|
| Active, not recruiting | 1/2 | 112 | US | Fruquintinib, HMPL-013, Tislelizumab, BGB-A317 | Hutchison Medipharma Limited, BeiGene | Triple Negative Breast Cancer, Endometrial Cancer, Solid Tumor, Unspecified, Adult, Colorectal Cancer | 07/24 | 11/24 | | |
NCT05581719 / 2022-003063-21: A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor Malignancy |
|
|
| Terminated | 1/2 | 14 | Europe, RoW | Allocetra-OTS, Nivolumab, Tislelizumab | Enlivex Therapeutics RDO Ltd., Enlivex Therapeutics RDO, Ltd. | Solid Tumor, Peritoneal Metastases, Peritoneal Cancer | 04/24 | 04/24 | | |
NCT04782804: Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative Recurrence |
|
|
| Recruiting | 1/2 | 30 | RoW | Capecitabine, XELODA, PD-1 Antibody（Tislelizumab）, Tislelizumab | Fudan University | Cholangiocarcinoma, Intrahepatic | 12/23 | 05/24 | | |
| Active, not recruiting | 1/2 | 71 | RoW | ZW25, Docetaxel, Tislelizumab, BGB-A317, Capecitabine, Oxaliplatin | BeiGene | Breast Cancer, Gastric Cancer, Gastroesophageal Junction Cancer | 12/23 | 12/26 | | |
TOUCH, NCT04425070: A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma |
|
|
| Active, not recruiting | 1/2 | 56 | RoW | ICE [ifosfamide+carboplatin+etoposide], GEMOX [gemcitabine+oxaliplatin], Tislelizumab | Antengene Corporation | Peripheral T-cell Lymphoma, NK/T-cell Lymphoma | 12/24 | 12/24 | | |
|
|
|
NCT05777707: Neoadjuvant Therapy of PD-1 Blockade Combined With Chemotherapy for Esophageal Carcinoma |
|
|
| Recruiting | 1/2 | 89 | RoW | PD-1 blockade, Albumin paclitaxel, Carboplatin/Nedaplatin | Beijing Friendship Hospital | Esophageal Carcinoma, Neoadjuvant Immunotherapy | 12/23 | 12/24 | | |
| Recruiting | 1/2 | 20 | RoW | Oxaliplatin, Levo-Leucovorin, 5-fluorouracil, Paclitaxel, Irinotecan, Tislelizumab | Fujian Cancer Hospital | Gastric Cancer Stage IV | 12/23 | 12/24 | | |
| Recruiting | 1/2 | 60 | RoW | IMX-110 combined with Tislelizumab, One Arm | Immix Biopharma, Inc., BeiGene, Novartis | Advanced Solid Tumor | 01/24 | 01/24 | | |
NCT05464433: Tislelizumab Combined With Mitoxantrone Hydrochloride Liposome in Extranodal Natural Killer/T Cell Lymphoma |
|
|
| Recruiting | 1/2 | 46 | RoW | Tislelizumab combined with Liposomal mitoxantrone hydrochloride, Maintenance of tislelizumab | Sun Yat-sen University | Extranodal Natural Killer T Cell Lymphoma | 01/24 | 01/25 | | |
NCT04666688: LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 80 | US | LYT-200, Tislelizumab, Gemcitabine/nab-paclitaxel | PureTech | Metastatic Cancer, Solid Tumor, Pancreatic Cancer, Urothelial Carcinoma, Head and Neck Cancer, Colorectal Cancer | 09/24 | 01/25 | | |
NCT06266871: SOX Combined With Tislelizumab and LDRT for Neoadjuvant Treatment of Locally Advanced Gastric Cancer |
|
|
| Not yet recruiting | 1/2 | 64 | NA | SOX+Tislelizumab+LDRT | West China Hospital | Gastric Cancer | 06/26 | 07/26 | | |
NCT04579757: Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors |
|
|
| Active, not recruiting | 1/2 | 135 | US | Surufatinib and Tislelizumab _ Part 1, HMPL-012, sulfatinib, BGB-A317, Surufatinib and Tislelizumab _ Part 2 | Hutchmed, BeiGene | Metastatic Solid Tumor, Colorectal Cancer, Neuroendocrine Tumors, Small Cell Lung Cancer, Gastric Cancer, Soft Tissue Sarcoma, Anaplastic Thyroid Cancer | 04/24 | 06/24 | | |
LATE, NCT05394415: Chemoradiation Plus Tislelizumab for Conversion Therapy of Locally Nonresectable ESCC |
|
|
| Recruiting | 1/2 | 30 | RoW | Tislelizumab, Paclitaxel, Carboplatin, Radiotherapy | Jiangsu Cancer Institute & Hospital | Esophageal Squamous Cell Carcinoma, Tislelizumab, Chemoradiation | 04/24 | 04/25 | | |
NCT06394791: Evaluation of The Efficacy And Safety of PD-1 + IL-2 Combined With Capox Treatment After Loop Colostomy Surgery in Left-sided Colorectal Cancer Patients Complicating Acute Obstruction |
|
|
| Not yet recruiting | 1/2 | 27 | NA | Tislelizumab + IL-2 Combined with Capox | The First Affiliated Hospital with Nanjing Medical University | Left-sided Colorectal Cancer Complicating Acute Obstruction | 12/24 | 12/25 | | |
NCT06364956: Phase Ib/II Trail of Neoadjuvant of Tislelizumab Combined With Palbociclib in Patients With Platinum-refractory Bladder Urothelial Carcinoma |
|
|
| Recruiting | 1/2 | 36 | RoW | Tislelizumab combined with two predefined dose groups of palbociclib, RP2D dose Of Tislelizumab combined with palbociclib was selected for phase II clinical trial. | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Bladder Cancer | 06/25 | 06/26 | | |
NCT06431243: A Clinical Study of Puesta Mesylate for Injection in Patients With Solid Tumors |
|
|
| Not yet recruiting | 1/2 | 120 | RoW | A group Purinostat Mesylate 6mg/m2, A group Purinostat Mesylate 8.4mg/m2, A group Purinostat Mesylate 11.2mg/m2, A group Purinostat Mesylate 15.0mg/m2, B group Purinostat Mesylate 6.0mg/m2, B group Purinostat Mesylate 8.4 mg/m2, B group Purinostat Mesylate 11.2 mg/m2, B group Purinostat Mesylate 15.0 mg/m2 | Chengdu Zenitar Biomedical Technology Co., Ltd | Advanced Solid Tumor | 05/26 | 11/26 | | |
NCT06471673: A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer |
|
|
| Recruiting | 1/2 | 18 | US | BC1 cell line, Bria-OTS regimen and CPI (tislelizumab), Bria-OTS regimen and CPI (tislelizumab) expansion cohort | BriaCell Therapeutics Corporation | Breast Cancer, Breast Tumor, Cancer of Breast, Cancer of the Breast, Malignant Tumor of Breast, Tumors, Breast | 04/25 | 10/25 | | |
NCT06456138: Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC |
|
|
| Not yet recruiting | 1/2 | 60 | RoW | Trametinib, Anlotinib, Tislelizumab | Shanghai Chest Hospital, BeiGene, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Novartis | KRAS Mutation-Related Tumors, Advanced Lung Cancer, Refractory Tumor | 06/26 | 12/28 | | |
NCT05746728: Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer |
|
|
| Not yet recruiting | 1/2 | 45 | RoW | Surufatinib, Tislelizumab | Huihua Xiong | Metastatic Triple-negative Breast Cancer | 08/24 | 08/25 | | |
NCT05661955: A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors. |
|
|
| Recruiting | 1/2 | 180 | RoW | BGB-A445, Tislelizumab | BeiGene | Urothelial Carcinoma, Renal Cell Carcinoma, Melanoma | 09/24 | 08/25 | | |
| Recruiting | 1/2 | 490 | RoW | LBL-007 Injection, LBL-007, Tislelizumab Injection, Tislelizumab, Cisplatin Injection, Cisplatin, Gemcitabine Hydrochloride for Injection, Gemcitabine Hydrochloride, Docetaxel injection, Docetaxel | Nanjing Leads Biolabs Co.,Ltd | Malignant Tumors | 10/24 | 06/25 | | |
NCT05505877: Phase I/IIa Study of BR790 in Combination With Tislelizumab in Adult Subjects With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 160 | RoW | BR790+Tislelizumab | Shanghai Gopherwood Biotech Co., Ltd. | Advanced Solid Tumor | 10/24 | 12/24 | | |
NCT05267054: Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB A1217) in Combination With Tislelizumab (BGB A317) or Rituximab |
|
|
| Active, not recruiting | 1/2 | 53 | RoW | Ociperlimab, BGB-A1217, Tislelizumab, BGB A317, Rituximab | BeiGene | Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma | 11/24 | 02/25 | | |
| Recruiting | 1/2 | 264 | RoW | CHOP+selinexor+5-Azacitidine, CHOP+duvelisib+5-Azacitidine, CHOP+chidamide+tislelizumab, standard CHOP | Ruijin Hospital, The First Affiliated Hospital of Nanchang University, Peking University Third Hospital, Wuhan TongJi Hospital, West China Hospital, Nanfang Hospital, Southern Medical University, Anhui Provincial Cancer Hospital, The First Affiliated Hospital of Soochow University, The Second Affiliated Hospital of Harbin Medical University, The First Affiliated Hospital of Xiamen University, The First Affiliated Hospital of Zhengzhou University, Beijing Tongren Hospital, Peking University People's Hospital, Sun Yat-sen University, The First Affiliated Hospital of Anhui Medical University, The First Hospital of Jilin University | Peripheral T Cell Lymphoma | 07/26 | 07/28 | | |
ChiCTR2100041675: Multicenter Clinical Study of Tislelizumab Combined with Nab-Paclitaxel and Carboplatin in Neoadjuvant Therapy Followed by Adjuvant Therapy with Tislelizumab in Triple Negative Breast Cancer (TNBC) |
|
|
| Recruiting | 1/2 | 62 | China | Nab-Paclitaxel /Carboplatin/Tislelizumab | Sun Yat-Set Memorial Hospital, Sun Yat-Sen University ; Sen Memorial Hospital, Sun Yat-Sen University, BeiGene (Beijing) Co., Ltd. | Triple Negative Breast Cancer | | | | |
NCT05906524: KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors |
|
|
| Not yet recruiting | 1/2 | 85 | RoW | KD6001, Tislelizumab, Bevacizumab | Shanghai Kanda Biotechnology Co., Ltd. | Advanced HCC, Other Solid Tumors | 04/25 | 12/25 | | |
NCT06030258: IN10018 Combination Therapy in Treatment-naïve ES-SCLC |
|
|
| Recruiting | 1/2 | 120 | RoW | IN10018, BI 853520, Tislelizumab, Carboplatin, Etoposide | InxMed (Shanghai) Co., Ltd. | Small Cell Lung Cancer Extensive Stage | 01/25 | 10/25 | | |
| Recruiting | 1/2 | 113 | RoW | BGB-10188, Zanubrutinib, BGB-3111, Brukinsa, Tislelizumab, BGB-A317, Tevimbra, Tizveni | BeiGene | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma, Advanced Solid Tumor | 05/25 | 12/25 | | |
NCT05982834: Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC |
|
|
| Recruiting | 1/2 | 43 | RoW | Disitamab Vedotin combined with fruquintinib and Tislelizumab | Fudan University | HER2-positive Gastric Cancer, Immunotherapy | 05/25 | 12/25 | | |
NCT05142696: A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab |
|
|
| Recruiting | 1/2 | 200 | Europe, US | [177Lu]Lu-DOTA-TATE, Lutathera, Lutetium (177Lu) oxodotreotide, Lutetium Lu 177 dotatate, Atezolizumab, [68Ga]Ga-DOTA-TATE, Carboplatin, Etoposide | Novartis Pharmaceuticals | Extensive Stage Small Cell Lung Cancer | 05/25 | 05/28 | | |
NCT05937438: Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma |
|
|
| Recruiting | 1/2 | 70 | RoW | Immune Checkpoint Inhibitors | Anhui Provincial Hospital | Esophageal Carcinoma | 09/25 | 12/26 | | |
NCT05982522: IN10018 Combination Therapy in Previously-treated Solid Tumors |
|
|
| Not yet recruiting | 1/2 | 72 | NA | IN10018, BI 853520, Nab-paclitaxel, Tislelizumab | InxMed (Shanghai) Co., Ltd. | Solid Tumor | 12/25 | 07/26 | | |
NCT05699811: IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 40 | RoW | MSC-IFNα, Nab paclitaxel, Abraxane, Cyclophosphamide, Anti-PD-1 monoclonal antibody, Toripalimab Injection, Sintilimab Injection, Camrelizumab Injection, Tislelizumab Injection | Chinese PLA General Hospital, Wuxi Sinotide New Drug Discovery Institutes | Locally Advanced or Metastatic Solid Tumors | 12/25 | 12/26 | | |
NCT05451173: Combining ICI With SBRT or HypoFrx-RT for ES NSCLC |
|
|
| Not yet recruiting | 1/2 | 83 | RoW | Stereotactic body radiotherapy, SBRT, Hypofractionated radiotherapy, HypoFrx-RT, Durvalumab | Alexander Chi | Non-small Cell Lung Cancer, Non-small Cell Carcinoma, Non-small Cell Lung Cancer Stage I, Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage III | 12/25 | 12/25 | | |
| Recruiting | 1/2 | 358 | Europe, RoW | BGB-A425, Tislelizumab, BGB-A317, LBL-007 | BeiGene | Locally Advanced or Metastatic Solid Tumors for Phase 1,Dose Escalation and Phase 2 Safety Lead-in, HNSCC, NSCLC and RCC Participants for Phase 2 | 03/26 | 12/27 | | |
| Recruiting | 1/2 | 475 | Europe, Canada, Japan, US, RoW | JDQ443, TNO155, tislelizumab | Novartis Pharmaceuticals | KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung, Cancer of the Lung, Lung Cancer, Neoplasms, Lung, Neoplasms, Pulmonary, Pulmonary Cancer, Pulmonary Neoplasms | 01/27 | 01/27 | | |
Liberty-201, NCT05609370: A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer |
|
|
| Recruiting | 1/2 | 226 | US, RoW | LBL-007, Tislelizumab, BGB-A-317, Bevacizumab biosimilar, Capecitabine, 5-Fluorouracil | BeiGene | Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer | 04/28 | 04/28 | | |
NCT05303844: Oncolytic Virotherapy Plus PD-1 Inhibitor for Patients With Refractory Malignant Ascites |
|
|
| Recruiting | 1b | 25 | RoW | H101, Tislelizumab | Fudan University | Refractory Malignant Ascites | 03/25 | 03/25 | | |
NCT05303090: Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib for Patients With Advanced Pancreatic Cancer |
|
|
| Recruiting | 1b | 25 | RoW | H101, Tislelizumab, lenvatinib | Fudan University | Pancreatic Ductal Adenocarcinoma | 03/25 | 03/25 | | |
NCT05675462: Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib as Second-line or Later Therapy in Patients With Advanced Hepatocellular Carcinoma |
|
|
| Recruiting | 1b | 25 | RoW | Oncorine, H101, Tislelizumab, Lenvatinib | Fudan University | Hepatocellular Carcinoma | 12/25 | 12/25 | | |
| Not yet recruiting | 1 | 15 | RoW | Tislelizumab, paclitaxel/docetaxel, cisplatin/carboplatin | Ruijin Hospital | Cervical Squamous Cell Carcinoma | 06/22 | 12/22 | | |
ChiCTR2000035684: An exploratory study on the efficacy, predictive markers and resistance mechanisms of Tislelizumab (anti-PD-1 antibody) combined with chemotherapy in the treatment of non-squamous non-small cell lung cancer patients with EGFR-sensitive mutations and previous EGFR-TKI treatment failure |
|
|
| Not yet recruiting | 1 | 40 | China | Tilelizumab combined with chemotherapy | Shanghai Chest Hospital, Shanghai Jiao Tong University ; Shanghai Chest Hospital, Three-year action plan to promote clinical skills and clinical innovation in municipal hospitals (2020-2022) major clinical research projects | lung cancer | | | | |
ChiCTR2200056506: A single-arm, open-label, single-center clinical study of surufatinib combined with tislelizumab in first-line treatment of patients with small cell lung cancer |
|
|
| Not yet recruiting | 1 | 20 | China | Surufatinib+Tislelizumab | Fifth Medical Center of Chinese People's Liberation Army General Hospital ; Fifth Medical Center of Chinese People's Liberation Army General Hospital, self-funded | Small-cell lung cancer | | | | |
| Completed | 1 | 27 | RoW | TetMYB Vaccine, BGB-A317 | Peter MacCallum Cancer Centre, Australia | Colorectal Cancer, Adenoid Cystic Carcinoma | 12/22 | 12/22 | | |
NCT05008861: Gut Microbiota Reconstruction for NSCLC Immunotherapy |
|
|
| Not yet recruiting | 1 | 20 | RoW | Capsulized Fecal Microbiota Transplant, Capsulized FMT, Anti-programmed cell death protein 1/programmed death-ligand 1 monoclonal antibody, Anti-PD-1/PD-L1 mAb, Anti-PD-1/PD-L1, Pembrolizumab, Nivolumab, Durvalumab, Sintilimab, Tislelizumab, Camrelizumab, Platinum based chemotherapy, Platinum based Chemotherapy drugs | Shanghai Zhongshan Hospital | Non-Small Cell Lung Cancer | 12/22 | 12/22 | | |
NCT03732664: ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer |
|
|
| Completed | 1 | 27 | RoW | Nivolumab, Pembrolizumab, Toripalimab, Sintilimab, Sintilimab, Tislelizumab, Durvalumab, BMS-936558, MDX1106, Keytruda | Second Affiliated Hospital, School of Medicine, Zhejiang University | High-Risk Resectable NSCLC | 03/23 | 03/23 | | |
NCT05120375: Assessment of Safety and Preliminary Efficacy With BAT6021 in Solid Tumor Patients in China |
|
|
| Terminated | 1 | 5 | RoW | BAT6021, Recombinant humanized monoclonal antibody against TIGIT injection | Bio-Thera Solutions | Solid Tumor | 04/23 | 04/23 | | |
NCT05273814: Study of Chemotherapy and PD-1 Inhibitor Combination With Anti-angiogenesis to Treat Elderly Lung Cancer |
|
|
| Not yet recruiting | 1 | 30 | RoW | Tislelizumab, PD-1 inhibitor, Pemetrexed, Chemotherapy, Bevacizumab, Anti-angiogenesis | Tianjin Medical University Cancer Institute and Hospital | Non-Small Cell Lung Cancer | 08/23 | 02/24 | | |
CICPD, NCT04381741: CD19 CAR-T Expressing IL7 and CCL19 Combined With PD1 mAb for Relapsed or Refractory Diffuse Large B Cell Lymphoma |
|
|
| Enrolling by invitation | 1 | 24 | RoW | CD19-7×19 CAR-T plus PD1 monoclonal antibody | Second Affiliated Hospital, School of Medicine, Zhejiang University | Diffuse Large B-cell Lymphoma | 09/23 | 09/23 | | |
NCT05798533: Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03) |
|
|
| Recruiting | 1 | 6 | RoW | Neo-T, Neoantigen targeting T cells Suspension for Intravenous Infusion, Toripalimab, JS001, Tislelizumab, BGB-A317 | BGI, China, Fudan University, Shanghai 10th People's Hospital | Solid Tumor | 09/23 | 09/24 | | |
NCT05431270: Dose Escalation/Expansion Study of PT199 (an Anti-CD73 mAb) Administered Alone and in Combination With a PD-1 Inhibitor (the MORNINGSTAR Study) |
|
|
| Recruiting | 1 | 40 | US | PT199, Tislelizumab | Phanes Therapeutics | Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma | 12/24 | 08/25 | | |
|
NCT04261439: A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab |
|
|
| Terminated | 1 | 60 | Europe, Japan, US, RoW | NIZ985, Spartalizumab, PDR001, Tislelizumab, VDT482 | Novartis Pharmaceuticals | In Escalation: All Patients With Solid Tumors and Lymphoma, In Expansion: Melanoma, Non-small Cell Lung Cancer | 12/23 | 12/23 | | |
NCT05131698: Clinical Study of the Efficacy and Safety of Transhepatic Arterial Chemoembolization Combined With Tislelizumab and Lenvatinib in Patients With Advanced Unresectable Hepatocellular Carcinoma |
|
|
| Active, not recruiting | 1 | 31 | RoW | Tislelizumab and Lenvatinib, Clinical Study of the Efficacy and Safety of Transhepatic Arterial Chemoembolization Combined With Tislelizumab and Lenvatinib in Patients With Advanced Unresectable Hepatocellular Carcinoma | Cancer Hospital of Guangxi Medical University | Tislelizumab, Lenvatinib, TACE, Advanced Unresectable Hepatocellular Carcinoma | 12/23 | 07/24 | | |
| Active, not recruiting | 1 | 20 | RoW | PD-1 plus stereotactic body radiotherapy | Shandong Cancer Hospital and Institute, BeiGene | Hepatocellular Carcinoma | 12/24 | 12/24 | | |
ChiCTR2200063055: Safety and efficacy of Tislelizumab in combination with doxorubicin in the first-line treatment of locally advanced or metastatic undifferentiated pleomorphic sarcoma: a prospective, single-arm, phase I study |
|
|
| Not yet recruiting | 1 | 10 | China | Tislelizumab, 200 mg, every three weeks | Beijing Jishuitan Hospital ; Beijing Jishuitan Hospital, Beigene Company | undifferentiated polymorphic sarcoma | | | | |
| Recruiting | 1 | 330 | US, RoW | BGB-15025, Tislelizumab, BGB-A317 | BeiGene | Advanced Solid Tumor | 03/25 | 03/25 | | |
NCT06344156: Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy as an Adjuvant Therapy for Pancreatic Cancer |
|
|
| Recruiting | 1 | 43 | RoW | Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy | Sichuan University | Pancreatic Cancer, Adjuvant Therapy | 04/26 | 04/27 | | |
NCT06233942: Study of BG-C9074 as Monotherapy and in Combination With Tislelizumab in Participants With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 150 | RoW | BG-C9074, Tislelizumab | BeiGene | Advanced Solid Tumor | 09/27 | 09/27 | | |
NCT06349837: Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors |
|
|
| Not yet recruiting | 1 | 9 | NA | Tislelizumab, PD-1 inhibitor, Low Dose Radiotherapy, LDRT, Stereotactic Ablative Radiotherapy, SBRT | Sichuan University | Solid Tumor | 03/25 | 03/26 | | |
NCT06356701: Tumor Nutritional Therapy in the First-line Treatment of Stage IV NSCLC |
|
|
| Recruiting | 1 | 120 | RoW | Cancer nutritional treatment regimen (Spirulina Bifidobacterium Capsules, Fish Oil Grape Seed Blueberry Soft Capsules, Ganoderma Spore Oil Soft Capsules) | The First Affiliated Hospital of Dalian Medical University | Long-Term Effects Secondary to Cancer Therapy | 12/24 | 12/25 | | |
| Active, not recruiting | 1 | 449 | US, RoW | Ociperlimab, Tislelizumab, Pemetrexed, Paclitaxel, Nab paclitaxel, Carboplatin, Cisplatin, Etoposide, 5fluorouracil, Oxaliplatin, Capecitabine | BeiGene | Locally Advanced and Metastatic Solid Tumors | 08/24 | 08/24 | | |
|
ChiCTR2300072770: Research on the use of targeted combined immunization before surgery for high-risk renal cancer to reduce the stage reduction of kidney tumors and improve the resectability rate of surgery |
|
|
| Not yet recruiting | 1 | 10 | China | Intravenous tirelizumab and oral pezopanib for 12 weeks | The First Affiliated Hospital of Xinjiang Medical University ; The First Affiliated Hospital of Xinjiang Medical University, Research Funding | renal carcinoma | | | | |
NCT04294160: A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer |
|
|
| Active, not recruiting | 1 | 122 | Europe, Canada, US, RoW | Dabrafenib, DRB436, Tafinlar, LTT462, Trametinib, TMT212, Mekinist, LXH254, TNO155, Spartalizumab, PDR001, Tislelizumab, VDT482, BGBA317 | Novartis Pharmaceuticals | BRAF V600 Colorectal Cancer | 10/24 | 10/24 | | |
NCT05508100: Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors |
|
|
| Completed | 1 | 38 | RoW | IO-108, IO-108 + pembrolizumab, IO-108 + Keytruda®, IO-108 + tislelizumab | Immune-Onc Therapeutics | Advanced Solid Tumor | 04/24 | 04/24 | | |
| Active, not recruiting | 1 | 46 | RoW | Sintilimab | The First Hospital of Jilin University | Tislelizumab, Locally Advanced Rectal Cancer, Total Neoadjuvant Treatment, PD-1 | 10/23 | 06/26 | | |
NCT05441046: Genakumab Alone and in Combination With Tislelizumab in Patients With Advanced Malignant Solid Tumors |
|
|
| Recruiting | 1 | 120 | RoW | Genakumab, Tislelizumab | GeneScience Pharmaceuticals Co., Ltd. | Malignant Solid Tumors | 06/24 | 03/25 | | |
NCT06463444: Precision Treatment of Unresectable HCC Guided by Multi-omics Deep Learning Models |
|
|
| Recruiting | 1 | 30 | RoW | HAIC + Tislelizumab +lenvatinib | Chen Xiaoping | HCC, Precision Therapy | 06/25 | 06/26 | | |
BGB-C354-101, NCT06422520: Phase 1 First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors |
|
|
| Not yet recruiting | 1 | 62 | NA | BGB-C354, Tislelizumab | BeiGene | Advanced Solid Tumor | 11/26 | 11/26 | | |
| Recruiting | 1 | 9 | RoW | NK510, Tislelizumab，atezolizumab or sugemalimab | Base Therapeutics (Shanghai) Co., Ltd., The General Hospital of Eastern Theater Command | NSCLC | 07/24 | 07/24 | | |
| Not yet recruiting | 1 | 74 | NA | BGB-R046, Tislelizumab | BeiGene | Solid Tumor | 12/27 | 12/27 | | |
NCT06427941: A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab, in Participants With Advanced or Metastatic Solid Tumors |
|
|
| Not yet recruiting | 1 | 140 | NA | BGB-B2033, Tislelizumab | BeiGene | Metastatic Hepatocellular Carcinoma, Advanced Hepatocellular Carcinoma, Alpha-fetoprotein (AFP)-Producing Gastric Cancer, Extragonadal Yolk Sac Tumors, Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer, Metastatic Solid Tumor | 10/26 | 10/26 | | |
CCGLC-007, NCT05533892: Nocardia Rubra Cell Wall Skeleton (N-CWS) Plus HAIC, Lenvatinib and Tislelizumab in Treating Patients With Advanced HCC |
|
|
| Recruiting | 1 | 30 | RoW | Nocardia rubra cell wall skeleton, N-CWS, Hepatic arterial infusion chemotherapy, HAIC, Lenvatinib, JieLiEn, Tislelizumab, BaiZeAn | Wan-Guang Zhang, Chinese Cooperative Group of Liver Cancer (CCGLC), Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province, M&R Pharm, Geneplus-Beijing Co. Ltd., Yuce Biotechnology Co., Ltd., Geneis, Simcere Pharmaceutical Co., Ltd, BeiGene, Haplox Biotechnology Co., Ltd. | Hepatocellular Carcinoma | 08/24 | 02/25 | | |
NCT06098898: Safety and Efficacy of NK510 to Treat Gastric Cancer |
|
|
| Enrolling by invitation | 1 | 9 | RoW | NK510, Tislelizumab，atezolizumab or Trastuzumab | Base Therapeutics (Shanghai) Co., Ltd., Shanghai 10th People's Hospital | Gastric Cancer | 11/24 | 11/24 | | |
HFB-200301-01, NCT05238883: A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 170 | Europe, US | HFB200301, Tislelizumab, BGB-A317 | HiFiBiO Therapeutics | Gastric Cancer, Renal Cell Carcinoma, Melanoma, Sarcoma, Testicular Germ Cell Tumor, Cervical Cancer, Mesothelioma, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma | 12/26 | 12/26 | | |
NCT05659628: CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL |
|
|
| Recruiting | 1 | 24 | RoW | CD19-7×19 CAR-T combined with Tislelizumab | Ningbo No. 1 Hospital, Zhejiang University | Diffuse Large B-cell Lymphoma | 12/24 | 12/26 | | |
ChiCTR2200063680: An exploratory clinical study on the efficacy and safety of tirelizumab combined with gemcitabine and albumin paclitaxel in the treatment of borderline resectable pancreatic cancer |
|
|
| Not yet recruiting | 1 | 30 | | Treatment programs | The Second Affiliated Hospital of the Army Medical University;, Self raised funds | Pancreatic cancer | | | | |
NCT05984602: A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer |
|
|
| Recruiting | 1 | 10 | US | Canakinumab, ACZ885, Tislelizumab, Nab-Paclitaxel, Gemcitabine | NYU Langone Health | Pancreatic Cancer | 02/25 | 06/25 | | |
NCT05935098: A Study of BGB-A3055, Alone and in Combination With Tislelizumab in Participants With Selected Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 318 | Europe, US, RoW | BGB-A3055, Tislelizumab, BGB-A317 | BeiGene | Advanced Solid Tumor, Metastatic Solid Tumor, Solid Tumor | 02/25 | 02/25 | | |
NCT05494762: Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid Tumors |
|
|
| Active, not recruiting | 1 | 55 | US, RoW | BGB-B167, Tislelizumab, BGB-A317 | BeiGene | Solid Tumor | 01/25 | 01/25 | | |
NCT05644626: Safety, Pharmacokinetics and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab in Participants With Solid Tumors in Chinese Participants |
|
|
| Withdrawn | 1 | 254 | NA | BGB-B167, Tislelizumab, BGB-A317 | BeiGene | Solid Tumors | 03/25 | 08/25 | | |
NCT05965102: Tirellizumab Combined With Chemotherapy Monotherapy for Non-small Cell Lung Cancer |
|
|
| Not yet recruiting | 1 | 31 | NA | Tirelizumab；Chemotherapy monotherapy | Second Affiliated Hospital of Guangzhou Medical University | Non-small Cell Lung Cancer | 04/25 | 06/25 | | |